Embody review: November 2026 prices, terms and what to verify
As of November 20, 2026, Embody’s current GLP-1 price is not confirmed here, because its page could not be read on November 20, 2026 (HTTP 429); the October 15 sale prices seen there ($129 tirzepatide, $79 semaglutide for a first month) could not be confirmed. This record shows no current figure rather than an older one presented as current; check the program’s own checkout before you enroll.
Released · Last reviewed · how we verify
Why no current price is shown
Its page could not be read on November 20, 2026 (HTTP 429); the October 15 sale prices seen there ($129 tirzepatide, $79 semaglutide for a first month) could not be confirmed. This site publishes no figure rather than an estimate or an outdated price presented as current. The August 2026 capture is kept in the open dataset as history, dated.
Limitations: five things to get in writing before you pay
Ask for the all-in price at your current dose and at the maintenance dose; the amount charged today and whether it recurs monthly or is prepaid; the licensed pharmacy that fills the prescription; the cancellation and refund terms, word for word; and what happens to your price when the dose goes up. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy.
Frequently asked
Does Embody charge a membership fee?
No required membership fee appeared on Embody’s page when it was read on November 20, 2026; the figures above are the full recurring charge before tax.
Does Embody take insurance?
Not for compounded medication. Embody is a cash-pay program in this dataset (August 2026 capture), and insurers do not cover compounded GLP-1s. If your plan covers Zepbound or Wegovy, check that first, because a covered brand prescription usually costs less than any cash price.
Which states does Embody serve?
Embody’s published coverage in the August 2026 capture was: not published. Telehealth prescribing depends on state licensing and changes often, so confirm your state at the start of the intake. The state pages list what each program publishes.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Embody pricing page (not readable on November 20, 2026)